Clinical appraisal of deficiencies of the basal analog insulin

References

• Shaw JE, Sicree RA, Zimmat PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res. Clin. Pract.87, 4–14 (2010).
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care31, 596–615 (2008).
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care34(Suppl. 1), S1–S100 (2011).
   PubMed Web of Science ®Google Scholar
• Garg S, Moser E, Dain MP, Rodionova A. Clinical experience with insulin glargine in Type 1 diabetes. Diabetes Technol. Ther.12, 835–846 (2010).
   PubMed Web of Science ®Google Scholar
• King AB. Insulin detemir: a better basal insulin for the management of diabetes? Expert Rev. Diab. Metab.4, 15–23 (2009).
   Google Scholar
• Poon K, King AB. Safety and efficacy profiles of long-acting basal insulin analogues glargine and detemir. Drug Healthcare Patient Safety2, 213–223 (2010).
   PubMedGoogle Scholar
• Heinnemann L, Linkeschova R, Rave K et al. Time–action profile of the long-acting insulin analogue insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care23, 644–649 (2000).
   PubMed Web of Science ®Google Scholar
• Porcellati F, Rossetti P, Busciantella NR et al. Comparison of pharmacokinetics and dynamics of long-acting insulin analogs glargine and detemir at steady state in Type 1 diabetes: a double-blind, randomized, crossover study. Diabetes Care30, 2447–2452 (2007).
   PubMed Web of Science ®Google Scholar
• Plank J, Bodenlenz M, Sinner F et al. A double-blind, randomized, dose–response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care28, 1107–1112 (2005).
   PubMed Web of Science ®Google Scholar
• Klein O, Lynge J, Endahl L, Damolt B, Nosek L, Heise T. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time–action profiles but less variability than insulin glargine in Type 2 diabetes. Diabetes Obes. Metab.9, 290–299 (2007).
   PubMed Web of Science ®Google Scholar
• Heise T, Pieber TR. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamps studies. Diabetes Obes. Metab.9, 648–659 (2007).
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. A randomized, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naïve people with Type 2 diabetes. Diabetologia51, 408–416 (2008).
   PubMed Web of Science ®Google Scholar
• Hollander P, Cooper J, Bregnhoj J, Pederson CB. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with Type 2 diabetes. Clin. Ther.30, 1976–1987 (2008).
   PubMed Web of Science ®Google Scholar
• Raskin P, Gylvin T, Weng W, Chaykin L. Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with Type 2 diabetes. Diabetes Metab. Res. Rev.25, 542–548 (2009).
   PubMed Web of Science ®Google Scholar
• King AB. Once-daily insulin detemir is comparable to once-daily insulin glargine in providing glycaemic control over 24 h in patients with Type 2 diabetes: a double-blind, randomized crossover study. Diabetes Obes. Metab.11, 69–71 (2008).
   Web of Science ®Google Scholar
• King AB. No higher dose requirements with insulin detemir than glargine in Type 2 diabetes: a cross-over, double-blind, and randomized study using continuous glucose monitoring. J. Diabetes Sci. Technol.4, 151–154 (2010).
   PubMedGoogle Scholar
• Rossetti P, Porcellati F, Fanelli C, Bolli B. Mechanisms and treatment of the afternoon phenomenon in patients with Type 1 diabetes mellitus using glargine as basal insulin. Diabetes54(Suppl. 1), A68 (2005).
   Web of Science ®Google Scholar
• Bolli GB, Kerr D, Thomas R et al. Comparison of a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) in Type 1 diabetes: a randomized open parallel multicenter study. Diabetes Care32, 1170–1176 (2009).
   PubMed Web of Science ®Google Scholar
• Housel AK, Shaw RF, Waterbury NV. Glucose control in patients with Type 2 diabetes based on frequency of insulin glargine administration. Diabetes Res. Clin. Pract.88, E17–E19 (2010).
   Google Scholar
• Lantus® Package Insert. Sanofi-Aventis US, Bridgewater, NJ, USA (2010).
   Google Scholar
• Schmidt MI, Hadji-Georgopoulos A, Rendell M, Margolis S, Kowarsk A. The dawn phenomenon, an early morning glucose rise: implications for diabetic intraday blood glucose variation. Diabetes Care4, 579–585 (1981).
   PubMed Web of Science ®Google Scholar
• Van Cauter E, Polonsky KS, Scheen AJ. Roles of circadian rhythmicity and sleep in human glucose regulation. Endocrinol. Rev.18, 716–738 (1997).
   PubMed Web of Science ®Google Scholar
• Carroll MF, Schade DS. The dawn phenomenon revisited: implication for diabetes therapy. Endocr. Prac.11, 55–64 (2005).
   PubMedGoogle Scholar
• Meyer L, Delbachian I, Lehert P, Cugnardey N, Brouin P, Guerci B. Continuous subcutaneous insulin infusion in Type 1 diabetes mellitus: insulin-sparing effect of metformin. Diabetes48(Suppl. 1), A351 (1999).
   Web of Science ®Google Scholar
• Hamilton J, Cummings E, Zdravkovic V, Finegood D, Daneman D. Metformin as an adjunct therapy in adolescents with Type 1 diabetes and insulin resistance: a randomized controlled trial. Diabetes Care26, 138–143 (2003).
   PubMed Web of Science ®Google Scholar
• Lund SS, Tarnow L, Astrup AS et al. Effect of adjunct metformin treatment in patients with Type-1 diabetes and persistent inadequate glycaemic control. A randomized study. PloS One3(10), e3363 (2008).
   PubMed Web of Science ®Google Scholar
• Perriello G, De Feo P, Torlone E et al. The dawn phenomenon in Type 1 (insulin-dependent) diabetes mellitus: magnitude, frequency, variability, and dependency on glucose counterregulation and insulin sensitivity. Diabetologia34, 21–28 (1991).
   PubMed Web of Science ®Google Scholar
• Heise T, Nosek L, Ronn BB et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with Type 1 diabetes. Diabetes53, 1614–1620 (2004).
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metfomin on complications in overweight patients with Type 2 diabetes. UKPDS 34. Lancet352, 854–865 (1998).
   PubMed Web of Science ®Google Scholar
• Carlson MG, Campbell PJ. Intensive insulin therapy and weight gain in IDDM. Diabetes42, 1700–1707 (1993).
   PubMed Web of Science ®Google Scholar
• Birkeland KI, Hanssen KF, Urdal P, Berg K, Valler S. A long-term, randomized, comparative study of insulin versus sulfonylurea therapy in Type 2 diabetes. J. Intern. Med.236, 305–313 (1994).
   PubMed Web of Science ®Google Scholar
• Hermansen K, Davies M. Does insulin detemir have a role in reducing risk of insulin-associated weight gain? Diabetes Obes. Metab.8, 209–217 (2007).
   Web of Science ®Google Scholar
• Tuomilehto J, Lindstrom J, Eriksson JG et al. Prevention of Type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med.344, 1343–1350 (2001).
   PubMed Web of Science ®Google Scholar
• Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int. J. Obes.26(Suppl. 3), S18–S24 (2002).
   PubMed Web of Science ®Google Scholar
• Blonde L, Merilainen M, Karwe V. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets – the TITRATE™ study. Diabetes Obes. Metab.11, 623–631 (2009).
   PubMed Web of Science ®Google Scholar
• Werner H, Weinstein D, Bentov I. Similarities and differences between insulin and IGF-I: structures, receptors, and signaling pathways. Arch. Physiol. Biochem.114, 17–22 (2008).
   PubMedGoogle Scholar
• Werner H, Maor S. The insulin-like growth factor-I receptor gene: a downstream target for oncogene and tumor suppressor action. Trends Endocrinol. Metab.17, 236–242 (2006).
   PubMed Web of Science ®Google Scholar
• Kurtzhals P, Schaffer L, Sorensen A et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes49, 999–1005 (2000).
   PubMed Web of Science ®Google Scholar
• Hemkens LG, Grouven U, Bender R et al. Risk of malignancies in patients with diabetes related with human insulin or insulin analogues: a cohort study. Diabetologia52, 1732–1744 (2009).
   PubMed Web of Science ®Google Scholar
• Jonasson JM, Ljung R, Talback M, Haglund B, Gudbjornsdottir S, Steineck G. Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia52, 1745–1754 (2009).
   PubMed Web of Science ®Google Scholar
• Colhoun HM; SDRN Epidemiology Group. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia52, 1755–1765 (2009).
   PubMed Web of Science ®Google Scholar
• Currie CJ, Poole CD, Gale EAM. The influence of glucose-lowering therapies on cancer risk in Type 2 diabetes. Diabetologia52, 1766–1777 (2009).
   PubMed Web of Science ®Google Scholar
• Home PD, Lagarenne P. Combined randomized controlled trial experience of malignancies in studies using insulin glargine. Diabetologia52, 2499–2506 (2009).
   PubMed Web of Science ®Google Scholar
• Dejgaard A, Lynggaard H, Rastam J, Thomsen MK. No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis. Diabetologia52, 2507–2512 (2009).
   PubMed Web of Science ®Google Scholar
• Giovannucci E, Harlan DM, Archer MC et al. Diabetes and cancer: a consensus report. Diabetes Care33, 1674–1685 (2010).
   PubMed Web of Science ®Google Scholar
• Mannucci E, Monami M, Balzi D et al. Doses of insulin and its analogues and cancer occurrence in insulin-treated Type 2 diabetic patients. Diabetes Care33, 1997–2003 (2010).
   PubMed Web of Science ®Google Scholar
• Montvale NJ. Drug Topics Red Book. Thomson Healthcare, NY, USA (2010).
   Google Scholar
• Birkeland K, Home PD, Wendisch U et al. Insulin degludec in Type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. Diabetes Care34(3), 661–665 (2011).
   PubMed Web of Science ®Google Scholar
• American Academy of Clinical Endocrinology. Diabetes mellitus clinical practice guidelines task force. Endocr. Pract.3(Suppl. 1), 3–68 (2007).
   Google Scholar